California Introduces New Regulations for PBMs

California has finally decided that pharmacy benefit managers should no longer operate like mysterious backstage magicians who pull pricing rabbits out of hats and then send everyone the bill. In 2025, the state moved from talking about PBM reform to building an actual oversight system, and by January 1, 2026, many of the biggest rules were already in effect. For patients, pharmacies, employers, insurers, and health plans, that shift matters because PBMs sit right in the middle of how prescription drug benefits are priced, managed, and delivered.

If you have ever wondered why a drug can cost one amount at the pharmacy counter, another amount on an insurance statement, and a third amount in a boardroom presentation with too many pie charts, PBMs are part of the reason. California’s new framework aims to make that system less opaque, less self-serving, and a lot harder to manipulate. The state is targeting spread pricing, rebate retention, steering to affiliated pharmacies, fee structures that reward higher costs, and weak oversight. That is a big deal in a market where prescription drug spending is both essential and maddeningly complicated.

What PBMs Do, and Why California Stepped In

PBMs, or pharmacy benefit managers, administer prescription drug benefits for health plans, insurers, and employer-sponsored plans. They negotiate with drug manufacturers, manage formularies, process claims, reimburse pharmacies, and often influence where and how patients get medications. On paper, that sounds efficient. In practice, critics have argued for years that the business model can reward opacity, encourage conflicts of interest, and make it harder for independent pharmacies and patients to get a fair shake.

California did not wake up one morning and suddenly discover PBMs existed. The state had already required certain PBMs under health plan contracts to register with regulators, and lawmakers had spent years debating broader oversight. But frustration kept building around hidden revenue streams, rebate arrangements, pharmacy reimbursement disputes, and patient steering to PBM-affiliated pharmacies. Lawmakers, pharmacy groups, patient advocates, and many payers increasingly argued that PBMs were too powerful, too vertically integrated, and too comfortable operating behind the curtain.

How California Got Here

From veto to overhaul

The road to reform was not exactly smooth. In 2024, Governor Gavin Newsom vetoed SB 966, a bill that would have imposed a licensing and oversight structure on PBMs. His veto message did not reject reform altogether. Instead, it argued that California needed more granular information to understand drug-market cost drivers and the role PBMs play in them. In plain English: the governor was saying, “I’m not saying no forever, but I would like more receipts.”

Then came 2025, and California returned with a sharper, more coordinated approach. Rather than relying on one bill alone, the state used a two-part strategy. AB 116, the health omnibus trailer bill, created the administrative framework for PBM licensure through the Department of Managed Health Care and expanded data reporting to the Department of Health Care Access and Information. SB 41 then layered on the business-practice rules that hit PBMs where it counts: pricing, rebates, steering, compensation, transparency, audits, and enforcement.

Together, those measures changed the conversation from “Should California regulate PBMs?” to “How quickly can everyone adjust to California regulating PBMs?”

What the New California PBM Rules Actually Do

1. PBMs are heading into a real licensing system

AB 116 requires PBMs that contract with health care service plans or health insurers to secure a license from the Department of Managed Health Care on or after January 1, 2027, or when the department finishes the licensure process, whichever comes later. That matters because licensure is not just paperwork. It gives the state a formal gatekeeping role, a defined enforcement structure, and an ongoing mechanism for financial reporting and compliance review.

California also created funding and data-reporting support for this framework. In other words, the state did not just announce a tough new attitude and hope for the best. It built the plumbing behind the wall so regulators can actually do the job.

2. Spread pricing is on the chopping block

Spread pricing is one of the PBM practices lawmakers love to hate. It happens when a PBM charges a health plan or insurer more for a drug than the PBM pays the dispensing pharmacy, then keeps the difference. California’s new law bans PBMs from conducting spread pricing in the state beginning January 1, 2026. New contracts cannot authorize it, and old contract terms allowing spread pricing are set to become void by January 1, 2029.

Why does this matter? Because spread pricing thrives in low-visibility environments. When the payer does not know what the pharmacy actually received, and the patient definitely does not know either, the PBM can profit from the gap. California wants less gap and more daylight.

3. Pass-through pricing is now the preferred model

SB 41 requires PBMs to use a passthrough pricing model. That means payments from the health plan or insurer for covered outpatient drugs are supposed to match what the PBM pays the pharmacy or provider, including any contracted professional dispensing fee, and those payments must be passed through in full rather than quietly adjusted through behind-the-scenes reconciliation games.

This is part of a broader delinking effort. California is trying to make PBM compensation look more like a clear administrative service fee and less like a mysterious profit engine fueled by the price of the drug itself.

4. Rebates must flow back, not disappear into the upholstery

Under SB 41, PBMs, group purchasing organizations, and affiliated entities must direct 100 percent of prescription drug manufacturer rebates to the payer or program when rebate negotiation has been delegated to them. The law says those funds are to be used to offset cost sharing, deductibles, coinsurance, and premiums for plan participants.

That provision strikes at one of the biggest policy complaints in the PBM world: the idea that rebates may look like savings in theory while functioning more like private margin in practice. California is taking the position that if a rebate exists because of a benefit arrangement, the benefit should actually benefit somebody other than the middleman.

5. PBM income is limited to defined fees

The law states that a PBM may not derive income from pharmacy benefit management services in California except through a pharmacy benefit management fee. That fee must be flat, defined, and tied to the bona fide value of the itemized services actually performed. It cannot be based on drug prices, retained rebates, or similar arrangements that reward higher spending or hidden margin.

That is a major philosophical shift. California is telling PBMs: you can get paid for your work, but not in ways that make everybody else wonder whether the cheaper drug mysteriously lost a knife fight in the formulary committee.

6. Anti-steering and nonaffiliated pharmacy protections are stronger

One of the most important sections of SB 41 protects nonaffiliated pharmacies. PBMs may not require plan participants to use only an affiliated pharmacy when nonaffiliated pharmacies are in the network. They may not financially induce patients to transfer prescriptions only to affiliated pharmacies, mislead patients into believing they must use an affiliated pharmacy, or deny preferred participation to a nonaffiliated pharmacy willing to accept the same terms and conditions as an affiliated one.

The law also bars discrimination against nonaffiliated pharmacies, including lower reimbursement for the same pharmacist service compared with an affiliated pharmacy. That is huge for independent and community pharmacies that have long argued the deck was stacked against them by vertically integrated PBM-pharmacy combinations.

7. Patients may see fairer cost-sharing calculations

SB 41 also reaches the consumer side. Beginning January 1, 2026, health plan contracts and insurance policies that provide prescription drug coverage may not calculate cost sharing at an amount that exceeds the actual rate paid by the plan or insurer for the prescription drug, with related net-price rules for arrangements that disclose the net amount paid. This is aimed at reducing the all-too-familiar frustration of patients paying cost sharing based on a higher number than the one actually used behind the scenes.

If California pulls this off well, patients may not suddenly start throwing ticker-tape parades in the pharmacy aisle, but they could see fewer pricing distortions at the counter.

8. Oversight, audits, reporting, and penalties now have sharper teeth

The DMHC may conduct routine and nonroutine surveys and examinations of PBMs and their fiscal and administrative affairs. Certain contracts must be open for inspection and audit. The Attorney General can seek injunctions, civil penalties, and other equitable relief, with statutory penalties ranging from $1,000 to $7,500 per violation. That gives the law more bite than a ceremonial “please do better” memo.

California also expanded the data picture. HCAI has said PBM data collection under AB 116 is anticipated to begin in 2028, including drug pricing, PBM fees, and pharmacy rebate data. That matters because effective reform depends on actual evidence, not just dramatic hearings and strongly worded headlines.

Who Benefits, and Who Is Nervous

Patients

Patients stand to benefit from limits on steering, cleaner cost-sharing rules, and a stronger chance that negotiated savings move back toward premiums and out-of-pocket costs. The best-case scenario is not just lower prices in theory, but fewer access barriers and a less confusing benefit experience.

Independent and community pharmacies

California’s anti-discrimination and anti-steering provisions are especially meaningful for smaller pharmacies. For years, many have argued that PBMs used network design, reimbursement differentials, and affiliated-pharmacy preferences to squeeze independents. The new rules attempt to level that playing field. Whether they fully succeed will depend on enforcement, but pharmacies now have a much stronger legal framework behind their complaints.

Health plans and insurers

Payers may welcome better visibility into fees, rebates, and PBM conduct. A pass-through model and fiduciary obligations could make contract negotiations cleaner and reduce uncertainty around hidden compensation. At the same time, plans will have to revisit agreements, compliance terms, and operational processes. Reform is good for transparency, but it is not exactly a lazy Sunday project for legal and procurement teams.

PBMs

PBMs have the most to lose from rules that narrow flexible revenue channels and expand oversight. Industry advocates have argued that blunt restrictions on PBM practices can raise premiums, reduce negotiating leverage against manufacturers, and create unintended consequences. That argument has not disappeared. It has simply moved from policy talking points into litigation and implementation debates.

The Legal Twist: California Won, Then Immediately Got Challenged

California’s reform package did not get a long honeymoon. On January 2, 2026, the Pharmaceutical Care Management Association sued California, challenging the fiduciary-duty provision as preempted by ERISA for self-insured employer plans. That lawsuit does not erase the law, but it does mean one of the most ambitious parts of California’s PBM framework faces meaningful legal scrutiny.

This is the classic American regulatory story: lawmakers pass a major reform, stakeholders issue celebratory or horrified statements, and then everyone meets again in federal court with much fancier fonts. For California, the outcome could shape how far states can go when regulating PBMs that touch employer-sponsored benefit plans.

Why California’s PBM Rules Matter Beyond California

California rarely does small healthcare policy experiments. When it regulates, other states watch, national trade groups react, and employers ask whether similar rules are coming to their zip code next. That is especially true here because PBM reform is now a national issue. Federal officials, lawmakers, employers, and courts are all wrestling with transparency, rebates, compensation, and fiduciary questions.

In early 2026, even the U.S. Department of Labor proposed a rule aimed at boosting transparency around PBM fees and compensation for employer-sponsored health plans. That does not mean California wrote the national playbook by itself, but the state is clearly part of a bigger push to force more sunlight into prescription-drug benefit management.

Experience on the Ground: What These Changes May Feel Like in Real Life

At the end of the day, policy lives or dies by lived experience. Here is what California’s new PBM framework may look like when it leaves the statute book and meets actual people.

First, imagine a patient with a chronic condition who has always been nudged toward a PBM-owned specialty pharmacy. Under the new rules, the patient may have a stronger argument for using another in-network pharmacy if that pharmacy can provide the same medication and services. The patient might still compare copays, delivery times, and convenience, but the choice becomes less about invisible corporate steering and more about what actually works for the person taking the drug.

Second, picture an independent pharmacist who has spent years watching reimbursements feel lower, fees feel stranger, and “preferred network” status feel suspiciously like a members-only club with a trap door. California’s anti-discrimination provisions and preferred-participation rules give that pharmacist more leverage. It does not guarantee instant financial relief, but it changes the tone of the relationship. Instead of begging for fair treatment, the pharmacy now has a statutory basis to demand it.

Third, think about an employer plan sponsor that has long suspected its PBM contract was written in a dialect best translated by archaeologists and litigators. California’s fiduciary language, disclosure expectations, and fee structure reforms could make those contracts easier to evaluate. The employer may ask sharper questions about rebates, administrative fees, specialty-drug arrangements, and pharmacy reimbursements. That alone can change bargaining power, because opacity tends to be bravest when nobody asks for itemized receipts.

Fourth, consider a health plan compliance officer who now has to review contracts, watch implementation dates, coordinate with counsel, and monitor what the DMHC does next. For that person, reform is not an abstract policy win. It is a calendar full of deadlines, contract amendments, operational revisions, and one very tired red pen. Still, better compliance architecture can eventually mean fewer disputes, cleaner audits, and less uncertainty about who is responsible when PBM conduct becomes a regulatory problem.

Fifth, imagine the patient at the pharmacy counter who does not care what a PBM is and would prefer never to learn the term at all. That person just wants the medication, a reasonable out-of-pocket cost, and no scavenger hunt across town. If California’s reforms work, that patient could encounter fewer bizarre pricing gaps, fewer “you must use this other pharmacy” messages, and a system that feels slightly less like a maze designed by accountants with trust issues.

That is the real test. Not whether policy experts admire the drafting, or whether lobbyists hate it with professional intensity, but whether people notice that the prescription benefit system becomes more understandable, more competitive, and more fair.

Conclusion

California’s new PBM rules are among the most consequential state-level efforts yet to reshape the prescription drug benefit market. The state has moved past loose transparency talk and into structural reform: licensure, pass-through pricing, rebate pass-through, anti-steering protections, inspection rights, and real enforcement tools. That does not guarantee instant savings or universal applause. Implementation will be messy, legal challenges will continue, and regulators still have hard work ahead.

Even so, the direction is unmistakable. California is trying to change PBM incentives, not just request better manners. If the framework survives legal scrutiny and gets enforced with discipline, it could become a model for other states looking to make drug benefit management less opaque and more accountable. In a healthcare system where too many prices arrive wearing disguises, that is a reform worth watching.

SEO Tags